oral FGFR1/2/3 kinase inhibitor

approved in oncology, 13.5 mg QD (14d+, 7d-)

from focused screen of ~20k cmpds and SBDD

Journal of Medicinal Chemistry

Incyte Corporation, Wilmington, US

Chemical structure of Pemigatinib Incyte FGFR1/2/3 kinase inhibitor

The Incyte FGFR1/2/3 kinase inhibitor, pemigatinib, is an oral kinase inhibitor that obtained an FDA accelerated approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: